Compare Taiwan Semiconductor Mfg. Co. Ltd. (TSM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Taiwan Semiconductor Mfg. Co. Ltd. vs Travere Therapeutics Inc. Common Stock — how do they compare? Taiwan Semiconductor Mfg. Co. Ltd. trades at $421.1 (market cap $2.02T), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 413.9× Travere Therapeutics Inc. Common Stock's market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.91% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Taiwan Semiconductor Mfg. Co. Ltd. for 111 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TSM | TVTX | |
|---|---|---|
Market Cap | $2.02T | $4.88B |
Volume | 8,566,236 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $485.80 | $67.52 |
52-Week Low | $275.06 | $26.79 |
Typical Hold Time | 111 Days | 0 Days |
Enterprise Value | $1.94T | $5.01B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSM trades at $430.00, down 3.23% on the day, with a bearish technical signal despite strong fundamentals. The company shows robust financial performance with 2025 revenue of $3.81T and net income of $1.70T, achieving 49.92% net margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $4.22 surpassing the $3.81 estimate. Analyst consensus remains strongly bullish with 72% buy ratings and a $578.43 price target, representing 34% upside potential from current levels.
TSM presents a compelling investment case driven by AI chip demand and technological leadership, though geopolitical risks and valuation concerns warrant caution. The stock's current bearish technical positioning contrasts with strong fundamentals and positive analyst sentiment, creating potential entry opportunities for long-term investors. Key risks include Taiwan-China tensions and competitive pressures in semiconductor manufacturing.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Taiwan Semiconductor Mfg. Co. Ltd.
Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
